OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/22/2025
Back to search
Official data from USPTO
AUTOLUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
AUTOLUS
ST13
US500000079380366Class
5, 40, 42, 44
Filing
79380366
Registration
7435787
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
03/22/2025
Classification
Registered
Trademark type
Word
Nice classes
5, 40, 42, 44
Filing date
09/05/2023
Registration date
07/09/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/09/2024
Last transaction
03/22/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
STADELI, MARTA
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Autolus Limited
Representatives
Rebecca Liebowitz Venable LLP
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical and veterinary preparations for therapeutic purposes for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; medical preparations for cell therapy for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; medical preparations for gene therapy for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; medical preparations for cancer therapies for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; cells for medical or clinical usecells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposesincluding viral vectorsculture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; vaccines
Class 40
Custom manufacture of therapeutic drugscell therapiescancer therapies and cancer vaccines
Class 42
Scientific and technological services and research and design relating theretomedical researchscientific researchanalysis and testing in the field of human and animal cellgene and cancer therapiespharmaceutical product developmentresearch and development of new products; industrial analysis and research services in the field of cellgene and cancer therapies; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccinesincluding personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services
Class 44
Medical services; veterinary services; medical and veterinary services in the nature of extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposesmedical services relating to the removaltreatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing medical advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines
Publications
History of USPTO decisions and trademark events.
29 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/04/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/01/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/01/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/01/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/01/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/10/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/20/2024
FIMP
FINAL DISPOSITION PROCESSED
12/20/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/10/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/23/2024
PUBO
PUBLISHED FOR OPPOSITION
04/23/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/16/2024
RFNT
REFUSAL PROCESSED BY IB
03/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/29/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/29/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/14/2024
RFRR
REFUSAL PROCESSED BY MPU
02/14/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/26/2024
CNRT
NON-FINAL ACTION WRITTEN
01/25/2024
DOCK
ASSIGNED TO EXAMINER
01/25/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/14/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/10/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/05/2023
Continuous trademark protection
Get notified about every new filing that threatens AUTOLUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.